公司资料
Pulmonx 股价、新闻与催化剂
- 股票代码:
- LUNG
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
2.23 USD (-7.85%)
收盘价
最后更新: 2026年8月17日
68M USD
市值
股价为何变动
As of Aug 17, 2026, LUNG closed down 7.85% at $2.23. No new same-company headline was identified in the current news window.
公司概览
Minimally Invasive COPD Treatment
Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy.
Zephyr Endobronchial Valve
The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung regions, allowing healthier areas to function more effectively. It has FDA premarket approval, is available in more than 25 countries and is incorporated into treatment guidelines.
Patient Selection Tools
The Chartis Pulmonary Assessment System evaluates collateral ventilation to help determine whether a patient is suitable for valve therapy. StratX reports use CT imaging to characterize emphysema distribution and fissure completeness.
Digital Care Support
The LungTraX platform supports patient identification, referral and treatment workflow. Together with Zephyr, Chartis and StratX, it gives Pulmonx an integrated model spanning screening, procedural planning and therapy.
未来催化剂
- Pulmonx’s next three months are about Zephyr Valve adoption, new physician-site expansion, and continued lung-volume-reduction procedure growth. The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。